Vectura Group plc Gemünden - Planned Closure

Vectura Group plc Gemünden - Planned Closure

 Chippenham, UK - 14 April 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces its intention to close its site in Gemünden, Germany, effective by March 2016.

The Gemünden site was acquired by Vectura as part of the acquisition of Activaero GmbH in March 2014 and is currently involved in the production of the Company's nebuliser devices, supporting clinical trials and marketing of the devices.  In order to improve manufacturing efficiencies, all activities currently carried out in Gemünden will be transferred to Vectura's facilities in Gauting, Germany, Chippenham UK and Cambridge UK, and to a contract manufacturing organisation for any commercial production.  As a result, the Company will close the site by March 2016.

 Dr Chris Blackwell, Chief Executive of Vectura, commented: "The decision to close our Gemünden site was a strategic and necessary one.  It will rationalise our business operations and deliver more cost-effective production of our nebulisers.  We retain the capabilities and capacity at our three remaining sites to support all our business operations.  I would like to thank all the employees at Gemündenfor their hard work and assure them of our continuing support as we prepare for the closure of the site in early 2016."

 -Ends-

 Enquiries

 

Vectura Group plc

+44 (0)1249 667700

Chris Blackwell, Chief Executive

 

Karl Keegan, Chief Corporate Development Officer

 

About Vectura

Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases).  This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $46 billion worldwide.1

Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies.  Vectura currently has disclosed development collaborations and license agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.

Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.

For further information, please visit Vectura's website at www.vectura.com.

References

[1] Pharmaview Commercial Landscape Series Respiratory Decision Resources 2013

 Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

 

 

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.